3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
7
Infections
7
Prostatic Neoplasms
4
Neutropenia
4
Lymphoma
4
Leukemia
4
Neoplasms, Plasma Cell
3
Febrile Neutropenia
3
Urinary Tract Infections
2
Pancreatic Neoplasms
2
Pancreatic Cyst
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Staphylococcal Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Rectal Neoplasms
1
Pulmonary Arterial Hypertension
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pain
1
Interventions
Lenalidomide
2
ofatumumab
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
SARS-CoV-2 inactivated vaccines
1
Influenza Vaccines
1
Immunoglobulins
1
Hizentra
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Agammaglobulinemia
×
Ciprofloxacin
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled